Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Pathol. 2017 Sep 5;243(2):230–241. doi: 10.1002/path.4947

Figure 3. Disease-free survival analyses of endometrial clear cell carcinoma patients stratified according to clinical features and molecular subtypes.

Figure 3

Kaplan–Meier disease-free survival curves for endometrial clear cell carcinoma patients stratified according to (A) stage of disease (stage I vs stage III/IV), (B) age (<65 years vs ≥65 years), (C) molecular subtypes defined using a surrogate model [38] (POLE, MMR-D, p53 wild-type (copy-number low (endometrioid)) and p53 abnormal (copy-number high (serous-like)), and (D) hierarchical clustering (POLE, copy-number high (serous-like) enriched, copy-number low (endometrioid)/ MSI (hypermutated) enriched). P-values of the log-rank test are shown. MMR-D, mismatch repair deficient; MSI, microsatellite instable.